KDIGO 2021 Clinical Hypertension Standard

Renal Blood Pressure Target Evaluator

High blood pressure is the second leading cause of kidney failure and transmits directly into delicate glomerular filtration capillaries. Enter your blood pressure, albuminuria, and clinical profile to determine your guideline-backed target and review protective medication strategies.

Load a Clinical Scenario:

Your Clinical Profile

mmHg
mmHg
Special Individualized Factors:

The 5 Rules of Accurate Blood Pressure Measurement

The KDIGO < 120 mmHg systolic guideline is based on standardized measurement. Taking your reading incorrectly can falsely elevate systolic pressure by 10 to 25 mmHg:

1
5 Minutes of Quiet Rest

Sit quietly in a chair with back supported for 5 full minutes without talking, checking your phone, or reading.

2
Feet Flat on the Floor

Never cross your legs or ankles during measurement. Crossed legs can raise systolic pressure by 5 to 8 mmHg.

3
Arm Supported at Heart Level

Rest your bare arm on a desk or table so the cuff is aligned horizontally with your heart.

4
Empty Your Bladder First

A full urinary bladder stimulates the sympathetic nervous system and can artificially spike blood pressure by 10 to 15 mmHg.

5
Take 2 Readings and Average Them

Take two measurements 1 to 2 minutes apart and record the average. Discard the first reading if you felt anxious.

Track Your Multi-Year Kidney Function Slope

Controlling blood pressure is the #1 way to flatten your rate of filtration loss. Use our free eGFR Slope & Trajectory Tool to see your multi-year decline rate.

Clinical Guidance Note: This evaluator is an educational tool based on published KDIGO clinical practice guidelines. Blood pressure targets and medication regimens must always be tailored by your nephrologist, cardiologist, or primary care physician. Never start, stop, or change doses of blood pressure medications without direct clinical supervision.

Frequently Asked Questions

Why did KDIGO lower the systolic blood pressure target to < 120 mmHg in CKD?

The KDIGO 2021 Clinical Practice Guideline lowered the systolic target to < 120 mmHg based on extensive trial evidence (notably the SPRINT trial), which demonstrated that intensive systolic blood pressure lowering significantly reduces cardiovascular events and all-cause mortality in chronic kidney disease patients without increasing permanent kidney injury.

Does the < 120 mmHg target apply to everyone with kidney disease?

No. The < 120 mmHg recommendation is based on standardized office blood pressure measurement. Clinical guidelines emphasize that targets must be individualized for patients with limited life expectancy, severe frailty, advanced age (> 75-80 years), or symptoms of orthostatic hypotension (dizziness upon standing). In these patients, a more relaxed target of < 130/80 mmHg or < 140/90 mmHg is commonly prescribed.

Why are ACE inhibitors and ARBs preferred over other blood pressure medications for kidneys?

Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) uniquely relax the efferent (outflow) arteriole of the kidney glomerulus. This reduces intraglomerular hydrostatic pressure, which directly prevents microscopic capillaries from bursting and dramatically cuts urine protein leakage (albuminuria).

Why does my serum creatinine temporarily rise after starting blood pressure medication?

When an ACE inhibitor, ARB, or SGLT2 inhibitor lowers the high pressure inside your kidney filters, filtration temporarily slows down, causing serum creatinine to rise by 10% to 30% (and eGFR to drop slightly). Nephrologists call this the "hemodynamic effect". As long as creatinine stabilizes within 30%, this confirms the drug is successfully removing stress from your nephrons, protecting them over the long term.